Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giampaolo Bianchini

Showing results (1-10 of 119) with videos related to

Pageof 12
Sort By:
Breast (Edinburgh, Scotland)|December 23, 2018
Is trastuzumab as a single agent obsolete in early breast cancer? NoGiampaolo Bianchini
The Lancet. Oncology|February 1, 2014
The immune system and response to HER2-targeted treatment in breast cancerGiampaolo Bianchini, Luca Gianni
Journal of the National Cancer Institute. Monographs|November 2, 2011
Surrogate markers for targeted therapy-based treatment activity and efficacyGiampaolo Bianchini, Luca Gianni
Cancer Cell|February 11, 2025
From intrinsic to adaptive clusters in breast cancerGiampaolo Bianchini, Giulia Viale, Matteo Dugo
Geroscience|April 24, 2024
Prognostic significance of a signature based on senescence-related genes in colorectal cancerZoltan Ungvari, Anna Ungvari, Giampaolo Bianchini, et al.
Nature Reviews. Clinical Oncology|November 10, 2021
Treatment landscape of triple-negative breast cancer - expanded options, evolving needsGiampaolo Bianchini, Carmine De Angelis, Luca Licata, et al.
Plos Medicine|January 30, 2026
Beyond the hype: Antibody-Drug Conjugates are advancing faster than our clinical strategyGiulia Notini, Giampaolo Bianchini, José Manuel Perez-Garcia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2016
New Strategies in Breast Cancer: ImmunotherapyLajos Pusztai, Thomas Karn, Anton Safonov, et al.
Geroscience|June 27, 2025
PCSK9 expression and cancer survival: a prognostic biomarker at the intersection of oncology and geroscienceZoltan Ungvari, Otília Menyhart, Andrea Lehoczki, et al.
Geroscience|January 8, 2025
Prognostic impact of glucagon-like peptide-1 receptor (GLP1R) expression on cancer survival and its implications for GLP-1R agonist therapy: an integrative analysis across multiple tumor typesZoltan Ungvari, Áron Bartha, Anna Ungvari, et al.
Pageof 12

Showing results (1-10 of 119) with videos related to

Sort By:
Pageof 12
Breast (Edinburgh, Scotland)|December 23, 2018
Is trastuzumab as a single agent obsolete in early breast cancer? NoGiampaolo Bianchini
The Lancet. Oncology|February 1, 2014
The immune system and response to HER2-targeted treatment in breast cancerGiampaolo Bianchini, Luca Gianni
Journal of the National Cancer Institute. Monographs|November 2, 2011
Surrogate markers for targeted therapy-based treatment activity and efficacyGiampaolo Bianchini, Luca Gianni
Cancer Cell|February 11, 2025
From intrinsic to adaptive clusters in breast cancerGiampaolo Bianchini, Giulia Viale, Matteo Dugo
Geroscience|April 24, 2024
Prognostic significance of a signature based on senescence-related genes in colorectal cancerZoltan Ungvari, Anna Ungvari, Giampaolo Bianchini, et al.
Nature Reviews. Clinical Oncology|November 10, 2021
Treatment landscape of triple-negative breast cancer - expanded options, evolving needsGiampaolo Bianchini, Carmine De Angelis, Luca Licata, et al.
Plos Medicine|January 30, 2026
Beyond the hype: Antibody-Drug Conjugates are advancing faster than our clinical strategyGiulia Notini, Giampaolo Bianchini, José Manuel Perez-Garcia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2016
New Strategies in Breast Cancer: ImmunotherapyLajos Pusztai, Thomas Karn, Anton Safonov, et al.
Geroscience|June 27, 2025
PCSK9 expression and cancer survival: a prognostic biomarker at the intersection of oncology and geroscienceZoltan Ungvari, Otília Menyhart, Andrea Lehoczki, et al.
Geroscience|January 8, 2025
Prognostic impact of glucagon-like peptide-1 receptor (GLP1R) expression on cancer survival and its implications for GLP-1R agonist therapy: an integrative analysis across multiple tumor typesZoltan Ungvari, Áron Bartha, Anna Ungvari, et al.
Pageof 12